Finally, all FD patients with nonsense mutations developed neutralizing antibodies against recombinant α-galactosidase A, whereas only three of the nine FD patients with missense mutations developed neutralizing ADAs (33.3%). This evidence concerns the gene AGPS and Fabry disease.